P3 Health Partners Inc. (NASDAQ:PIII) Sees Large Growth in Short Interest

P3 Health Partners Inc. (NASDAQ:PIII) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 27,237 shares, an increase of 72.0% from the January 15th total of 15,836 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily trading volume, of 29,534 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily trading volume, of 29,534 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.5% of the company’s stock are sold short.

Hedge Funds Weigh In On P3 Health Partners

A hedge fund recently raised its stake in P3 Health Partners stock. Trinity Financial Advisors LLC grew its stake in shares of P3 Health Partners Inc. (NASDAQ:PIII) by 4.6% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 26,678 shares of the company’s stock after acquiring an additional 1,178 shares during the quarter. Trinity Financial Advisors LLC owned about 0.37% of P3 Health Partners worth $239,000 as of its most recent SEC filing. 7.75% of the stock is owned by institutional investors.

P3 Health Partners Stock Performance

PIII stock traded up $0.04 during trading hours on Friday, hitting $2.05. 1,434 shares of the stock were exchanged, compared to its average volume of 84,214. P3 Health Partners has a 12 month low of $1.52 and a 12 month high of $12.36. The company has a current ratio of 0.32, a quick ratio of 0.32 and a debt-to-equity ratio of 2.29. The firm has a market capitalization of $14.79 million, a P/E ratio of -0.05 and a beta of 0.89. The company has a 50-day simple moving average of $3.32 and a two-hundred day simple moving average of $6.24.

P3 Health Partners (NASDAQ:PIII) last released its quarterly earnings results on Thursday, November 13th. The company reported ($9.67) EPS for the quarter, missing analysts’ consensus estimates of ($8.70) by ($0.97). The business had revenue of $345.25 million for the quarter, compared to the consensus estimate of $346.64 million. P3 Health Partners had a negative return on equity of 302.33% and a negative net margin of 9.07%. On average, analysts forecast that P3 Health Partners will post -0.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PIII. Weiss Ratings reiterated a “sell (e+)” rating on shares of P3 Health Partners in a research note on Thursday, January 22nd. BTIG Research restated a “neutral” rating on shares of P3 Health Partners in a research note on Friday, December 12th. Finally, Lake Street Capital cut their price objective on P3 Health Partners from $20.00 to $12.50 and set a “buy” rating for the company in a research report on Monday, November 17th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, P3 Health Partners currently has a consensus rating of “Hold” and an average price target of $12.50.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.